The first registered vaccine against COVID-19. https://sputnikvaccine.com/ Cohen J. Vaccine wagers on coronavirus surface protein pay off. Science. 2020;370:894–5. Article CAS Google Scholar Callaway E. The underdog coronavirus vaccines that the world will need if front runners stumble. ...
The article discusses the controversy surrounding the COVID-19 vaccine and its potential impact on public trust in other vaccines. The AstraZeneca vaccine, marketed as COVISHIELD in India, was found to have rare cases of blood clots with low platelets. This...
However, concerns are raised about a rush to deploy a COVID-19 vaccine. Applying “Quick fix” and “short cuts” can lead to errors with disastrous consequences.Previous article in issue Next article in issue Keywords COVID-19 SARS-CoV-2 coronavirus vaccine platform technology clinical trials ...
Article CAS Google Scholar Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80–82 (2021). Article CAS Google Scholar Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature ...
19 vaccines. In this review, we provided an up-to-date summary for current COVID-19 vaccines, discussed the biological basis and clinical impact of SARS-CoV-2 variants and subvariants, and analyzed the effectiveness of various vaccine booster regimens against different SARS-CoV-2 strains. ...
On August 23, 2021, the FDA approved its first COVID-19 vaccine, the BNT162b2 - COVID-19 Vaccine, mRNA for individuals 12 years and above. The second approval was given on January 31, 2022, to the mRNA-1273 - COVID-19 Vaccine, mRNA in individuals 18 years and above. ...
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study Lancet, 398 (10309) (2021), pp. 1407-1416 View PDFView articleGoogle Scholar 30 J. Corchado-Garcia, D. Zemmour, T. Hughes, et al. Analysis of...
I won’t teach you the ins and outs of immunology in this quick read but I will give you an easy-to-understand breakdown so this article, the COVID-19 vaccine, and basic immune theory clicks in your brain forevermore—I hope! Once you understand the pieces, the whole picture of the ...
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–59. Article PubMed CAS Google Scholar Dai YC, Lin YC, Ching LL, Tsai JJ, Ishikawa K, Tsai WY, et al....
clinical trials is an mRNA vaccine delivered via lipid nanoparticles. To eradicate pandemics, present and future, a successful vaccine platform must enable rapid discovery, scalable manufacturing and global distribution. Here, we review current approaches to COVID-19 vaccine development and highlight ...